Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial von Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

Volltext

1969PTargeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option von Liu, S V, Duruisseaux, M, Tolba, K, Branden, E, Goto, Y, Weinberg, B A, Renouf, D J, Doebele, R C, Heining, C, Schlenk, R F, Cheema, P K, Cadranel, J, Jones, M R, Drilon, A E, Trombetta, D, Muscarella, L A, Cseh, A, Solca, F, Laskin, J J

Volltext

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets von Rekhtman, Natasha, Pietanza, Maria C, Hellmann, Matthew D, Naidoo, Jarushka, Arora, Arshi, Won, Helen, Halpenny, Darragh F, Wang, Hangjun, Tian, Shaozhou K, Litvak, Anya M, Paik, Paul K, Drilon, Alexander E, Socci, Nicholas, Poirier, John T, Shen, Ronglai, Berger, Michael F, Moreira, Andre L, Travis, William D, Rudin, Charles M, Ladanyi, Marc

Volltext

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer von Drilon, Alexander, Oxnard, Geoffrey R, Tan, Daniel S.W, Loong, Herbert H.F, Johnson, Melissa, Gainor, Justin, McCoach, Caroline E, Gautschi, Oliver, Besse, Benjamin, Cho, Byoung C, Peled, Nir, Weiss, Jared, Kim, Yu-Jung, Ohe, Yuichiro, Nishio, Makoto, Park, Keunchil, Patel, Jyoti, Seto, Takashi, Sakamoto, Tomohiro, Rosen, Ezra, Shah, Manisha H, Barlesi, Fabrice, Cassier, Philippe A, Bazhenova, Lyudmila, De Braud, Filippo, Garralda, Elena, Velcheti, Vamsidhar, Satouchi, Miyako, Ohashi, Kadoaki, Pennell, Nathan A, Reckamp, Karen L, Dy, Grace K, Wolf, Jürgen, Solomon, Benjamin, Falchook, Gerald, Ebata, Kevin, Nguyen, Michele, Nair, Binoj, Zhu, Edward Y, Yang, Luxi, Huang, Xin, Olek, Elizabeth, Rothenberg, S. Michael, Goto, Koichi, Subbiah, Vivek

Volltext

Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements von Chang, Jason C., Zhang, Lei, Drilon, Alexander E., Chi, Ping, Alaggio, Rita, Borsu, Laetitia, Benayed, Ryma, Travis, William D., Ladanyi, Marc, Antonescu, Cristina R.

Volltext

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers von Wirth, Lori J, Sherman, Eric, Robinson, Bruce, Solomon, Benjamin, Kang, Hyunseok, Lorch, Jochen, Worden, Francis, Brose, Marcia, Patel, Jyoti, Leboulleux, Sophie, Godbert, Yann, Barlesi, Fabrice, Morris, John C, Owonikoko, Taofeek K, Tan, Daniel S.W, Gautschi, Oliver, Weiss, Jared, de la Fouchardière, Christelle, Burkard, Mark E, Laskin, Janessa, Taylor, Matthew H, Kroiss, Matthias, Medioni, Jacques, Goldman, Jonathan W, Bauer, Todd M, Levy, Benjamin, Zhu, Viola W, Lakhani, Nehal, Moreno, Victor, Ebata, Kevin, Nguyen, Michele, Heirich, Dana, Zhu, Edward Y, Huang, Xin, Yang, Luxi, Kherani, Jennifer, Rothenberg, S. Michael, Drilon, Alexander, Subbiah, Vivek, Shah, Manisha H, Cabanillas, Maria E

Volltext

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions von Hechtman, Jaclyn F, Benayed, Ryma, Hyman, David M, Drilon, Alexander, Zehir, Ahmet, Frosina, Denise, Arcila, Maria E, Dogan, Snjezana, Klimstra, David S, Ladanyi, Marc, Jungbluth, Achim A

Volltext

Characterization of on-target adverse events caused by TRK inhibitor therapy von Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A.

Volltext

Selective RET kinase inhibition for patients with RET-altered cancers von Subbiah, V., Velcheti, V., Tuch, B.B., Ebata, K., Busaidy, N.L., Cabanillas, M.E., Wirth, L.J., Stock, S., Smith, S., Lauriault, V., Corsi-Travali, S., Henry, D., Burkard, M., Hamor, R., Bouhana, K., Winski, S., Wallace, R.D., Hartley, D., Rhodes, S., Reddy, M., Brandhuber, B.J., Andrews, S., Rothenberg, S.M., Drilon, A.

Volltext

COVID-19 in patients with lung cancer von Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

Volltext

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium von Guo, Robin, Berry, Lynne D., Aisner, Dara L., Sheren, Jamie, Boyle, Theresa, Bunn, Paul A., Johnson, Bruce E., Kwiatkowski, David J., Drilon, Alexander, Sholl, Lynette M., Kris, Mark G.

Volltext

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms von Durham, Benjamin H., Lopez Rodrigo, Estibaliz, Picarsic, Jennifer, Abramson, David, Rotemberg, Veronica, De Munck, Steven, Pannecoucke, Erwin, Lu, Sydney X., Pastore, Alessandro, Yoshimi, Akihide, Mandelker, Diana, Ceyhan-Birsoy, Ozge, Ulaner, Gary A., Walsh, Michael, Yabe, Mariko, Petrova-Drus, Kseniya, Arcila, Maria E., Ladanyi, Marc, Solit, David B., Berger, Michael F., Hyman, David M., Lacouture, Mario E., Erickson, Caroline, Saganty, Ruth, Ki, Michelle, Dunkel, Ira J., Santa-María López, Vicente, Mora, Jaume, Haroche, Julien, Emile, Jean-Francois, Decaux, Olivier, Geissmann, Frederic, Savvides, Savvas N., Drilon, Alexander, Diamond, Eli L., Abdel-Wahab, Omar

Volltext

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies von Jordan, Emmet J, Kim, Hyunjae R, Arcila, Maria E, Barron, David, Chakravarty, Debyani, Gao, JianJiong, Chang, Matthew T, Ni, Andy, Kundra, Ritika, Jonsson, Philip, Jayakumaran, Gowtham, Gao, Sizhi Paul, Johnsen, Hannah C, Hanrahan, Aphrothiti J, Zehir, Ahmet, Rekhtman, Natasha, Ginsberg, Michelle S, Li, Bob T, Yu, Helena A, Paik, Paul K, Drilon, Alexander, Hellmann, Matthew D, Reales, Dalicia N, Benayed, Ryma, Rusch, Valerie W, Kris, Mark G, Chaft, Jamie E, Baselga, José, Taylor, Barry S, Schultz, Nikolaus, Rudin, Charles M, Hyman, David M, Berger, Michael F, Solit, David B, Ladanyi, Marc, Riely, Gregory J

Volltext

Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics von Polk, Jess B., Campbell, Jonah, Drilon, Alexander E., Keating, Peter, Cambrosio, Alberto

Volltext

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial von Subbiah, Vivek, Gainor, Justin F, Oxnard, Geoffrey R, Tan, Daniel S W, Owen, Dwight H, Cho, Byoung Chul, Loong, Herbert H, McCoach, Caroline E, Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y, Kherani, Jennifer F, Huang, Xin, Kang, Suhyun, Drilon, Alexander

Volltext

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 von Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

Volltext

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors von Doz, François, van Tilburg, Cornelis M, Geoerger, Birgit, Højgaard, Martin, Øra, Ingrid, Boni, Valentina, Capra, Michael, Chisholm, Julia, Chung, Hyun Cheol, DuBois, Steven G, Gallego-Melcon, Soledad, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Hong, David S, Italiano, Antoine, Kang, Hyoung Jin, Nysom, Karsten, Thorwarth, Anne, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Gavrilovic, Igor T, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, Drilon, Alexander, Perreault, Sebastien

Volltext

Decision‐making as discovery: Vetting clinical research in a leading precision oncology service von Cambrosio, Alberto, Campbell, Jonah, Drilon, Alexander E., Keating, Peter, Polk, Jess B.

Volltext

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) von Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D.M., Hechtman, J., Wei, G., Cam, N.R., Christiansen, J., Luo, D., Maneval, E.C., Bauer, T., Patel, M., Liu, S.V., Ou, S.H.I., Farago, A., Shaw, A., Shoemaker, R.F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A.L.

Volltext

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer von Suzawa, Ken, Offin, Michael, Lu, Daniel, Kurzatkowski, Christopher, Vojnic, Morana, Smith, Roger S, Sabari, Joshua K, Tai, Huichun, Mattar, Marissa, Khodos, Inna, de Stanchina, Elisa, Rudin, Charles M, Kris, Mark G, Arcila, Maria E, Lockwood, William W, Drilon, Alexander, Ladanyi, Marc, Somwar, Romel

Volltext